Journal of Clinical Oncology
Articles in this Issue
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study
PURPOSE Efficacy of immune checkpoint inhibitors in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) is limited. The NEPTUNES study evaluated combin...
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay
PURPOSE Escalation of adjuvant systemic therapies (eg, with cyclin-dependent kinase 4 and 6 inhibitors) is now indicated for patients with clinically defined high-risk estrogen receptor–po...
Erratum: Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round
Reply to: Pediatric and Adolescent Considerations for the Revised ASCO Guidelines
Brown Paper Bags
Have you ever received a gift from a patient? Tell us about the experience—was it an exchange of kindness, gratitude, humor, or perhaps shock or confusion? Read as @DrSGraff shares what she has found...
Precision and Combination Strategies for Immune Checkpoint Inhibitors in Prostate Cancer
Phase II Study of <sup>177</sup> Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers
PURPOSE 177 Lu-DOTA(0)-Tyr(3)-octreotate ( 177 Lu-DOTATATE) is a somatostatin receptor (SST...
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer
PURPOSE The US Food and Drug Administration (FDA) approved inavolisib with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA...
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials
PURPOSE Outcome of patients with localized osteosarcoma is challenging. The role of mifamurtide is still a matter of debate. Two prospective trials were carried out in Italy (ISG/O...
Reply to: “UKALL 2011: Flawed Noninferiority and Overlooked Interactions Undermine Conclusions” and “Understanding the Potential Importance of Pharmacokinetic Variability in the Setting of ALL”
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial
The FLAME trial hypothesized that focal boosting of intraprostatic tumor lesion(s) in addition to standard external beam radiotherapy (EBRT) improves biochemical disease-free survival (bDFS). In this...
Understanding the Potential Importance of Pharmacokinetic Variability in the Setting of ALL
Pediatric and Adolescent Considerations for the Revised ASCO Guidelines
Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma
PURPOSE Systematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non–small cell lung cancer. We aimed to investigate wh...